XBIT News and Press, XBiotech Inc. From 08/18/20

Sanofi agrees to acquire Principia Bio for $3.68 billion Sanofi ( SNY ) announced that it has agree to buy Principia Biopharma Inc. ( PRNB ) for $3.68 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. Sanofi believes that the acquisition...

Thinly traded micro cap XBiotech (NASDAQ: XBIT ) is up  16%  premarket on modestly higher volume in reaction to its announcement that it has identified True Human antibodies, derived without modification from humans, that could potentially be used to treat COVID-19. More news...

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood AUSTIN, Texas, Aug. 17, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy again...

Results from a large-scale study involving more than 35K severely ill COVID-19 patients demonstrated that the early administration of convalescent plasma, derived from patients who recovered from the infection and who generated antibodies against SARS-CoV-2, lowered the mortality rate. ...

Investment Thesis XBiotech Inc. 5-year share price performance. Source: TradingView . XBiotech ( XBIT ) represents an interesting investment opportunity taking into account its past performance, current progress and niche field of drug development. The company develops proprietary Tru...

Grifols ( GRFS +1.9% ) announces the delivery of the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin to U.S. healthcare agencies for use in COVID-19 clinical trials, expected to launch in the coming weeks. More news on: Grifols, S.A., Kamada Ltd., XBiotech Inc., ...

XBiotech makes a crucial breakthrough in True Human antibodies Development XBiotech Inc. (XBIT) reported that it has made an important breakthrough in the development of True Human antibodies, novel inflammation countering mechanism. This new type of antibody seeks to replace previous-gene...

After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 AUSTIN, Texas, July 22, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in ...

XBiotech ( XBIT +2.6% ) announces encouraging results from research conducted in Switzerland that supports the rationale of interleukin-1 alpha (IL-1⍺) blockade for reducing brain damage and neurological deficit after a stroke. More news on: XBiotech Inc., Healthcare stocks news...

Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy AUSTIN, Texas, July 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today findings published in the prestigious American...